CClinicalTrials.gg
RecruitingNCT06512558AR-GBSUpdated Dec 31, 2025

Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery

An interventional study of Additional MRI with gadolinium injection and 3D camera imaging in Subclinical Breast Cancer Lesion, sponsored by Centre Jean Perrin. Recruiting at 1 site in France. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Centre Jean Perrin · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
Female
01

Study summary

Breast cancer is diagnosed by imaging at a non-palpable stage in more than half of all cases. Surgical removal requires preoperative guidance. Generally, preoperative guidance is performed using a metal guide under local anaesthetic and radiological control. This type of guidance has several limitations. For the patient, it can be painful and traumatic. The procedure involves two departments: radiology and the operating theatre, which poses logistical constraints. What's more, between 10% and 40% of patients require repeat surgery for unhealthy margins, raising the question of the effectiveness of the tracking procedure. The investigators propose to develop a non-invasive intraoperative guidance system: Augmented Reality, which will provide a 3D vision with virtual transparency of the breast during surgery, thanks to real-time fusion of preoperative imaging with video from a camera located in the operating room. The process is illustrated below.

Illustration of the general principle of the augmented reality system for locating non-palpable breast lesions. The images above represent a preliminary test carried out on the computer outside the operating room. This is an initial research prototype which has not yet been validated and is not suitable for routine use.

02

Conditions studied

  • Subclinical Breast Cancer Lesion
03

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Major women
  • Requiring conservative surgical management of a subclinical cancerous breast lesion (not palpable), the histology of which has been previously proven by anatomopathology;
  • Having a breast MRI indication at the time of the breast assessment performed at the Centre Jean Perrin
  • Ability to give informed consent to participate in the study,
  • Membership of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Patients with breast neoplasia during pregnancy;
  • Persons deprived of their liberty or under guardianship or incapable of giving consent;
  • Refusal to participate.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Interventional

    Procedure: Additional MRI with gadolinium injection and 3D camera imaging

Interventions

  • ProcedureAdditional MRI with gadolinium injection and 3D camera imaging

    The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.

05

What researchers measure

Primary outcomes

  1. Feasibility of the study

    The feasibility of the study will be considered to have been achieved if the investigators obtain at least 4 successes among the 5 patients who benefited from the augmented reality procedure pre- and intraoperatively. Success is defined at both preoperative and intraoperative levels. Success in the preoperative phase is defined by: visibility of registration landmarks (clavicle, sternal fork, sternum, xyphoid process and areolar-nipple plate). Success in the intraoperative phase is defined by: non-prolongation of anesthesia time due to the study procedure.

    Time frame: 1 year

Secondary outcomes

  1. Time measurement of the study procedure

    Measurement of the time required to complete the various stages of the study procedure and surgery : device set-up, marking of registration marks on the patient's bust with a dermographic pencil, 3D acquisition of the patient's bust using a 3D camera, duration of the procedure, anesthesia time.

    Time frame: 1 year

  2. Creating a phantom

    Success of creating a phantom is deemed to have been achieved if the breast Phantom including all clinical features

    Time frame: 1 year

  3. Assessment of the feasibility of images fusion

    Assessment of the feasibility of fusing supine 3D breast MRI images and post-MRI ultrasound (second look) with target lesion detection.

    Time frame: 1 year

06

Study locations

1 of 1 sites recruiting
  • Centre Jean PERRIN
    Clermont-Ferrand, 63011, France
    Recruiting
07

Registry details

Key details

Study ID
NCT06512558
Lead sponsor
Centre Jean Perrin
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Nov 14, 2024
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Céleste PINARD
Contact
Celeste.PINARD@clermont.unicancer.fr
0473278005
Dr Sabrina MADAD-ZADEH
Contact
0473278005

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion